Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12510566 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL7150986 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL1582415 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL4388634 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL7150977 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL468706 | 0.98 | PYGB (0.67) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL7149670 | 0.98 | PYGB (0.67) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL31477900 | 0.88 | PYGB (0.64) | PYGBGAAAKR1B1CA12CA1 | |
| SCHEMBL4307948 | 0.86 | PYGB (0.62) | PYGBGAA | |
| SCHEMBL9302995 | 0.86 | CA1 (0.60) | PYGBGAACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762395-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | Sanofi (FR) | 2021-01-13 | — | — | EP | claimed |
| WO-2019170731-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI (FR) | 2019-09-12 | — | — | WO | claimed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | claimed |
| EP-0119650-A2 | Galactosyl-insulin conjugates useful in treating diabetics | THE PROCTER & GAMBLE COMPANY (US) | 1984-09-26 | — | — | EP | claimed |
| EP-4748381-A2 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748382-A2 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-12636301-B2 | 5′-modified carbocyclic ribonucleotide derivatives and methods of use | SANEGENE BIO USA INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4731764-A2 | DOUBLE STRANDED RNA TARGETING PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) AND METHODS OF USE THEREOF | Sanegene Bio USA Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3826720-B1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TMPRSS6 AND IRON CHELATORS | SILENCE THERAPEUTICS GMBH (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4717773-A2 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF A TARGET GENE COMPRISING PHOSPHORODITHIOATE LINKAGES | Silence Therapeutics GmbH (DE) | 2026-04-01 | — | — | EP | disclosed |
| US-20260078372-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2026-03-19 | — | — | US | disclosed |
| US-12569570-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012037254-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-8106022-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20090247614-A1 | Folate Conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090239814-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005055947-A2 | ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS | YU RUEY J (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-0119650-A2 | Galactosyl-insulin conjugates useful in treating diabetics | THE PROCTER & GAMBLE COMPANY (US) | 1984-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078372-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | LPAR2, LPCAT1, LPAR1 | PYGB 1466/4885GAA 2288/4885AKR1B1 2856/4885 |
| US-12569570-B2 | Compositions and methods for targeted RNA delivery | LDLR, ASGR1, PCSK9 | PYGB 3543/4885GAA 1561/4885AKR1B1 544/4885 |
| US-20090239814-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | LPXN, ZYX, OSTC | PYGB 263/4885GAA 348/4885AKR1B1 2156/4885 |
| US-20090247614-A1 | Folate Conjugates | FOLR2, FOLR1, NSUN2 | PYGB 3602/4885GAA 3667/4885AKR1B1 1228/4885 |
| US-12636301-B2 | 5′-modified carbocyclic ribonucleotide derivatives and methods of use | NSUN2, RNASE1, RNASEL | PYGB 1052/4885GAA 967/4885AKR1B1 1658/4885 |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | PYGB 263/4885GAA 348/4885AKR1B1 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.